BO-653: Chugai

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 342-346

  Meng, Charles Q ^a  

^a AtheroGenics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DI TERT BUTYL 2,3 DIHYDRO 5 HYDROXY 2,2 DIPENTYLBENZOFURAN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PROBUCOL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; RESTENOSIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; BENZOFURANS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CORONARY RESTENOSIS; HUMANS;

EID: 0037740976     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. 265461 Design and synthesis of novel dihydrobenzofuranol antioxidants. Tamura K, Kato Y, Ishikawa A, Kato Y, Himori M, Yoshida M, Cynshi O, Higashida A, Aiono R, Ohba Y ACS 214th 1997 Abs MEDI-218
2. 268512 2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: Design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Noguchi N, Iwaki Y, Takahashi M, Komuro E, Kato Y, Tamura K Cynshi O, Kodama T, Niki E Arch Biochem Biophys 1997 342 2 236-243
3. 276455 Effects of high fat diet and a novel antioxidant (BO653) on ischemia reperfusion injury of rat kidney. Koshiba K, Kumano K, Watanabe T, Takashima Y, Cynshi O Jpn J Nephrol 1997 39 5 455-463
4. 276456 Inhibition of oxidation of low-density lipoprotein by a novel antioxidant, BO-653, prepared by theoretical design. Noguchi N, Okimoto Y, Tsuchiya J, Cynshi O, Kodama T, Niki E Arch Biochem Biophys 1997 347 1 141-147. In vitro and in vivo studies showing that BO-653 is a novel antioxidant and might act as a potent inhibitor of development of atherosclerosis.
5. 298757 Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Cynshi O, Kawabe Y, Suzuku T, Takashima Y, Kaise H, Nakamura M, Ohba Y, Kato Y, Tamura K, Hayasaka A, Higashida A et al Proc Natl Acad Sci USA 1998 95 17 10123-10128. The antioxidant BO-653 was anti-atherogenic in three different animal models.
6. 335537 Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Lonn EM, Yusuf S Can J Cardiol 1997 13 10 957-965
7. 348499 A potent, novel antioxidant (BO-653) has effects on neointimal thickening in a stent porcine restenosis model. Miyauchi K, Lewis DA, Rajamannan NM, Kantor B, Camrud LJ, Camrud AR, Daida H, Yamaguchi H, Holmes DR Jr, Schwartz RS 72nd Am Heart Assoc 1999 Atlanta Abs 2460
8. 353562 Antioxidant BO-653 and human macrophage-mediated LDL oxidation. Muller K, Carpenter KL, Freeman MA, Mitchinson MJ Free Radical Res 1999 30 1 59-71
9. 353567 A novel antioxidant (BO-653) suppressed proliferation of VSMS and neointimal thickening in rabbit balloon injury model. Nakamura N, Sekimori R, Sato T, Kaise H, Yamaguchi H, Kodama T, Cynshi O Circulation 1998 98 17 Suppl 1 1741
10. 378869 Chugai Pharmaceutical Co Ltd, Tokyo, Japan: As of July 2000. Chugai Pharmaceutical Co Ltd Company Brochure 2000 July 01
11. 390462 Efficacy of a novel antioxidant on vascular remodeling after coronary angioplasty: Possible role of endothelial function and collagen accumulation. Miyauchi K, Schwartz RS, Aihara K, Kurata T, Sato H, Yamaguchi H, Daida H Circulation 2000 102 18 Abs 915
12. 409785 Japanese global strategy update - Chugai Pharmaceutical. Pharma Jpn 2001 1746 1-3
13. 434336 Investors' information: Development pipeline. Chugai Pharmaceutical Co Ltd Company World Web Site 2001 November 12
14. 446848 Effect of BO-653 and probucol on c-myc and PDGF-A messenger RNA of the iliac artery after balloon denudation in cholesterol-fed rabbits. Inoue K, Cynshi O, Kawabe Y, Nakamura M, Miyauchi K, Kimura T, Daida H, Hamakubo T, Yamaguchi H, Kodama T Atherosclerosis 2002 161 2 353-363
15. 446853 Anti-atherogenic antioxidants regulate the expression and function of proteasome α-type subunits in human endothelial cells. Takabe W, Kodama T, Hamakubo T, Tanaka K, Suzuki T, Aburatani H, Matsukawa N, Noguchi N J Biol Chem 2001 276 44 40497-40501
16. 446889 Macrophage scavenger receptor (SR-A I/II) deficiency reduced diet-induced atherosclerosis in C57BL/6J mice. Kamada N, Kodama T, Suzuki H J Atherosclerosis Thrombosis 2001 8 1 1-6
17. 446896 Stability and reactivity of aryloxyl radicals derived from a novel antioxidant BO-653 and related compounds. Effects of substituent and side chain in solution and membranes. Watanabe A, Noguchi N, Fujisawa A, Kodama T, Tamura K, Cynshi O, Niki E J Am Chem Soc 2000 122 23 5438-5442
18. 446905 Gene expression induced by BO-653, probucol and BHQ in human endothelial cells. Takabe W, Mataki C, Wada Y, Ishii M, Izumi A, Aburatani H, Hamakubo T, Niki E, Kodama T, Noguchi N J Atherosclerosis Thrombosis 2000 7 4 223-230
19. 448015 Investor presentation - April 2002. Roche Holding AG Company Presentation 2002 April 16
20. 459056 US-05574178: 4-Alkoxy-2,6-di-t-butylphenol derivative. Cynshi O, Kato Y, Ohba Y, Tamura K, Yoshida M US Patent 1995 August 02
21. 460177 New drugs in the R&D pipeline. Pharma Jpn 2002 1806 1-20
22. 466457 Chugai: Development pipeline. Chugai Pharmaceutical Co Ltd Company World Wide Web Site 2002 October 11
23. 469126 Communication from BO-653 global project leader. Chugai Pharmaceutical Co Ltd Company Communication 2002 November 01 Dr Toshihiko Komori, the global project leader for BO-653, Chugai Pharmaceuticals Ltd, stated that in Chugai's published paper [446848], the percentage of BO-653 dietary supplement had been reported in error as 1%. However, this should have been reported as 0.5.
24. 469128 BO-653, a novel antioxidant suppressed VSMC proliferation and neointimal thickening in rabbit and porcine models. Nakamura M, Sato T, Kaise H, Kim MJ, Sekimora R, Kawabe Y, Yamaguchi H, Miyauchi K, Schwarz RS, Kodama T, Cynshi O Atherosclerosis 2000 151 1 109
25. 469932 Chugai development pipeline. Chugai Pharmaceutical Co Ltd Company World Wide Web Site 2002 November 13
26. 482652 Message from the CEO. Chugai Pharma USA Company World Wide Web Site 2003 February 14
27. 483108 Chugai: Development pipeline. Chugai Pharmaceutical Co Ltd Company World Wide Web Site 2002 November 01